Home Casteddu.com	FAQ My Amedeo About	Flying Publisher
	The Medical Article of the Year 2008: Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447:661-78. Free full-text

Ovarian Neoplasms

Free Subscription Articles published in Gynecol Oncol Retrieve available abstracts of 474 articles: HTML format

Single Articles

July 2008
1. TAYLOR DD , Gercel-Taylor C
   MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer.
   Gynecol Oncol. 2008;110:13-21.
   PubMed     Related articles    Abstract available
   
   
   June 2008
2. JOHNSON CC , Kessel B, Riley TL, Ragard LR, et al
   The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial.
   Gynecol Oncol. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
3. MARKMAN M
   Mandating prospectively defined endpoints for ovarian cancer phase 2 trials: A strategy to improve the quality of gynecologic cancer clinical research.
   Gynecol Oncol. 2008;.
   PubMed     Related articles   
   
   
   
4. PARK JY , Kim DY, Suh DS, Kim JH, et al
   Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: Oncologic safety and reproductive outcomes.
   Gynecol Oncol. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
5. HAVRILESKY LJ , Whitehead CM, Rubatt JM, Cheek RL, et al
   Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.
   Gynecol Oncol. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
6. LEFFERS N , Lambeck AJ, de Graeff P, Bijlsma AY, et al
   Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation.
   Gynecol Oncol. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
7. HAMILTON CA , Maxwell GL, Chernofsky MR, Bernstein SA, et al
   Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer.
   Gynecol Oncol. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
8. CHAN KK , Tam KF, Tse KY, Ngan HY, et al
   The role of regular physical examination in the detection of ovarian cancer recurrence.
   Gynecol Oncol. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
9. COHN DE , Hall NC, Povoski SP, Seamon LG, et al
   Novel perioperative imaging with (18)F-FDG PET/CT and intraoperative (18)F-FDG detection using a handheld gamma probe in recurrent ovarian cancer.
   Gynecol Oncol. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
10. QU D , Qu H, Fu M, Zhao X, et al
    Increased expression of Nlp, a potential oncogene in ovarian cancer, and its implication in carcinogenesis.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
11. DORUM A , Tonstad S, Liavaag AH, Michelsen TM, et al
    Bilateral oophorectomy before 50 years of age is significantly associated with the metabolic syndrome and Framingham risk score: a controlled, population-based study (HUNT-2).
    Gynecol Oncol. 2008;109:377-83.
    PubMed     Related articles    Abstract available
    
    
    May 2008
12. DEVINE KM , Smicun Y, Hope JM, Fishman DA, et al
    S1P induced changes in epithelial ovarian cancer proteolysis, invasion, and attachment are mediated by Gi and Rac.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
13. GOTLIEB WH , Saumet J, Beauchamp MC, Gu J, et al
    In vitro metformin anti-neoplastic activity in epithelial ovarian cancer.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
14. MURDOCH WJ , Van Kirk EA, Isaak DD, Shen Y, et al
    Progesterone facilitates cisplatin toxicity in epithelial ovarian cancer cells and xenografts.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
15. MOORE KN , Reid MS, Fong DN, Myers TK, et al
    Ovarian cancer in the octogenarian: Does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply?
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
16. BOYD J
    Whence epithelial ovarian carcinoma?
    Gynecol Oncol. 2008;109:161-3.
    PubMed     Related articles   
    
    
    
17. RIEDINGER JM , Eche N, Basuyau JP, Dalifard I, et al
    Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study.
    Gynecol Oncol. 2008;109:194-8.
    PubMed     Related articles    Abstract available
    
    
    April 2008
18. DURRANT D , Richards JE, Walker WT, Baker KA, et al
    Mechanism of cell death induced by cis-3, 4', 5-trimethoxy-3'-aminostilbene in ovarian cancer.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
19. WENZEL L , Huang HQ, Cella D, Walker JL, et al
    Validation of FACT/GOG-AD subscale for ovarian cancer-related abdominal discomfort: A Gynecologic Oncology Group study.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
20. BULL PHELPS SL , Schorge JO, Peyton MJ, Shigematsu H, et al
    Implications of EGFR inhibition in ovarian cancer cell proliferation.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
21. MORRIS R , Alvarez RD, Andrews S, Malone J, et al
    Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
22. WRIGHT JD , Tian C, Mutch DG, Herzog TJ, et al
    Carboplatin dosing in obese women with ovarian cancer: A Gynecologic Oncology Group study.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
23. LEE HP , Seo SS, Ryu SY, Kim JH, et al
    Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
24. HARLEY I , Rosen B, Risch HA, Siminovitch K, et al
    Ovarian cancer risk is associated with a common variant in the promoter sequence of the mismatch repair gene MLH1.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
25. BRISTOW RE , Peiretti M, Zanagnolo V, Salani R, et al
    Transverse colectomy in ovarian cancer surgical cytoreduction: Operative technique and clinical outcome.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
26. CHAN JK , Teoh D, Hu JM, Shin JY, et al
    Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
27. PUCA R , Nardinocchi L, Pistritto G, D'Orazi G, et al
    Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    March 2008
28. DOWDY SC , Loewen RT, Aletti G, Feitoza SS, et al
    Assessment of outcomes and morbidity following diaphragmatic peritonectomy for women with ovarian carcinoma.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
29. BOUCHARDY C , Fernandez S, Merglen A, Usel M, et al
    Increased risk of second cancer among patients with ovarian borderline tumors.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
30. LI AJ , Scoles DR, Armstrong KU, Karlan BY, et al
    Androgen receptor cytosine-adenine-guanine repeat polymorphisms modulate EGFR signaling in epithelial ovarian carcinomas.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
31. FERRANDINA G , Ludovisi M, Corrado G, Carone V, et al
    Prognostic role of ca125 response criteria and RECIST criteria: Analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
32. LITKOUHI B , Litkouhi B, Fleming E, Welch WR, et al
    Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasms.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
33. SINGH RK , Lange TS, Kim KK, Shaw SK, et al
    A novel indole ethyl isothiocyanate (7Me-IEITC) with anti-proliferative and pro-apoptotic effects on platinum-resistant human ovarian cancer cells.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
34. CHOI M , Fuller CD, Thomas CR Jr, Wang SJ, et al
    Conditional survival in ovarian cancer: Results from the SEER dataset 1988-2001.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
35. SENGUPTA S , Michener CM, Escobar P, Belinson J, et al
    Ovarian cancer immuno-reactive antigen domain containing 1 (OCIAD1), a key player in ovarian cancer cell adhesion.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
36. WOODS DC , Alvarez C, Johnson AL
    Cisplatin-mediated sensitivity to TRAIL-induced cell death in human granulosa tumor cells.
    Gynecol Oncol. 2008;108:632-40.
    PubMed     Related articles    Abstract available
    
    
    February 2008
37. SHAH CA , Allison KH, Garcia RL, Gray HJ, et al
    Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: Association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
38. ALBERTS DS , Marth C, Alvarez RD, Johnson G, et al
    Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of pro
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
39. KONECNY GE , Agarwal R, Keeney GA, Winterhoff B, et al
    Claudin-3 and claudin-4 expression in serous papillary, clear-cell, and endometrioid endometrial cancer.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
40. OEI AL , Sweep FC, Massuger LF, Olthaar AJ, et al
    Transient human anti-mouse antibodies (HAMA) interference in CA 125 measurements during monitoring of ovarian cancer patients treated with murine monoclonal antibody.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
41. MODESITT SC , Sill M, Hoffman JS, Bender DP, et al
    A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
42. SOEDA S , Nakamura N, Ozeki T, Nishiyama H, et al
    Tumor-associated macrophages correlate with vascular space invasion and myometrial invasion in endometrial carcinoma.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
43. STAMMER K , Edassery SL, Barua A, Bitterman P, et al
    Selenium-Binding Protein 1 expression in ovaries and ovarian tumors in the laying hen, a spontaneous model of human ovarian cancer.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
44. LINCH M , Stavridi F, Hook J, Barbachano Y, et al
    Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
45. FADER AN , Gruenigen VV, Gibbons H, Abushahin F, et al
    Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
46. AYHAN A , Gultekin M, Dursun P, Dogan NU, et al
    Metastatic lymph node number in epithelial ovarian carcinoma: does it have any clinical significance?
    Gynecol Oncol. 2008;108:428-32.
    PubMed     Related articles    Abstract available
    
    
    
47. GIL OD , Lee C, Ariztia EV, Wang FQ, et al
    Lysophosphatidic acid (LPA) promotes E-cadherin ectodomain shedding and OVCA429 cell invasion in an uPA-dependent manner.
    Gynecol Oncol. 2008;108:361-9.
    PubMed     Related articles    Abstract available
    
    
    January 2008
48. TAYLOR SA , Marrinan CH, Liu G, Nale L, et al
    Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
49. BARTON CA , Hacker NF, Clark SJ, O'Brien PM, et al
    DNA methylation changes in ovarian cancer: Implications for early diagnosis, prognosis and treatment.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
50. MARKMAN M
    Evidence-based chemotherapy administration in advanced ovarian cancer: An impressive past, a disquieting present and an uncertain future.
    Gynecol Oncol. 2008;.
    PubMed     Related articles   
    
    
    
51. BLACK D , Levine DA, Nicoll L, Chou JF, et al
    Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
52. TAKAI N , Ueda T, Nishida M, Nasu K, et al
    beta-Hydroxyisovalerylshikonin has a profound anti-growth activity in human endometrial and ovarian cancer cells.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
53. KALLI KR , Oberg AL, Keeney GL, Christianson TJ, et al
    Folate receptor alpha as a tumor target in epithelial ovarian cancer.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
54. ZHOU B , Sun Q, Cong R, Gu H, et al
    Hormone replacement therapy and ovarian cancer risk: A meta-analysis.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
55. MARKMAN M
    Duration of second or greater complete clinical remission in ovarian cancer: Exploring potential endpoints for clinical trials.
    Gynecol Oncol. 2008;.
    PubMed     Related articles   
    
    
    
56. SABBATINI P , Harrison ML
    Response to Dr. Markman regarding "Duration of second or greater complete clinical remission in ovarian cancer: Exploring potential endpoints for clinical trials.
    Gynecol Oncol. 2008;.
    PubMed     Related articles   
    
    
    
57. PARK JY , Kim EN, Kim DY, Suh DS, et al
    Comparison of the validity of magnetic resonance imaging and positron emission tomography/computed tomography in the preoperative evaluation of patients with uterine corpus cancer.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
58. SECORD AA , Blessing JA, Armstrong DK, Rodgers WH, et al
    Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: A Gynecologic Oncology Group study.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
59. HOCHSTER H , Chen TT, Lu JM, Hills D, et al
    Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
60. BUTTIN BM , Moore MJ
    Thalidomide-induced reversible interstitial pneumonitis in a patient with recurrent ovarian cancer.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
61. LEE YK , Park NH, Kim JW, Song YS, et al
    Gamma-knife radiosurgery as an optimal treatment modality for brain metastases from epithelial ovarian cancer.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
62. OZBUDAK IH , Karaveli S, Simsek T, Erdogan G, et al
    Neoangiogenesis and expression of hypoxia-inducible factor 1alpha, vascular endothelial growth factor, and glucose transporter-1 in endometrioid type endometrium adenocarcinomas.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
63. CACERES A , Zhou Q, Iasonos A, Gerdes H, et al
    Colorectal stents for palliation of large-bowel obstructions in recurrent gynecologic cancer: An updated series.
    Gynecol Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    December 2007
64. PINKE DE , Kalloger SE, Francetic T, Huntsman DG, et al
    The prognostic significance of elongation factor eEF1A2 in ovarian cancer.
    Gynecol Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
65. SALANI R , Axtell A, Gerardi M, Holschneider C, et al
    Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer.
    Gynecol Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
66. FALCHOOK GS , Wolff RA, Varadhachary GR
    Clinicopathologic features and treatment strategies for patients with pancreatic adenocarcinoma and ovarian metastases.
    Gynecol Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
67. SCHMELER KM , Sun CC, Bodurka DC, T Deavers M, et al
    Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.
    Gynecol Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
68. ASHWORTH A , Balkwill F, Bast RC Jr, Berek JS, et al
    Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007.
    Gynecol Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
69. GUIRGUIS A , Elishaev E, Oh SH, Tseng GC, et al
    Use of gene expression profiles to stage concurrent endometrioid tumors of the endometrium and ovary.
    Gynecol Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
70. EISENHAUER EL , Abu-Rustum NR, Sonoda Y, Aghajanian C, et al
    The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer.
    Gynecol Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
71. DELOIA JA , Zamboni WC, Jones JM, Strychor S, et al
    Expression and activity of taxane-metobolizing enzymes in ovarian tumors.
    Gynecol Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
72. RISUM S , Hogdall C, Loft A, Berthelsen AK, et al
    Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography-A prospective study.
    Gynecol Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
73. GERSHENSON DM
    Fallopian tube cancer: stepchild or mother?
    Gynecol Oncol. 2007;107:386-7.
    PubMed     Related articles   
    
    
    
74. LAMBERT LA , Mansfield PF
    Peritoneal dissemination of non-carcinoid primary appendiceal cancer.
    Gynecol Oncol. 2007;107:592.
    PubMed     Related articles   
    
    
    November 2007
75. MOORE RG , Brown AK, Miller MC, Skates S, et al
    The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.
    Gynecol Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
76. NUMNUM TM , Makhija S, Lu B, Wang M, et al
    Improved anti-tumor therapy based upon infectivity-enhanced adenoviral delivery of RNA interference in ovarian carcinoma cell lines.
    Gynecol Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
77. EZAWA S , Suzuki N, Ohie S, Higashiguchi A, et al
    A synthetic retinoid, TAC-101 (4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid), plus cisplatin: Potential new therapy for ovarian clear cell adenocarcinoma.
    Gynecol Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
78. GREENAWAY J , Moorehead R, Shaw P, Petrik J, et al
    Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer.
    Gynecol Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
79. BAMIAS A , Koutsoukou V, Terpos E, Tsiatas ML, et al
    Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy
    Gynecol Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
80. TOMSOVA M , Melichar B, Sedlakova I, Steiner I, et al
    Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.
    Gynecol Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
81. LI Y , Liang J, Kang S, Dong Z, et al
    E-cadherin gene polymorphisms and haplotype associated with the occurrence of epithelial ovarian cancer in Chinese.
    Gynecol Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
82. VAN ALTENA AM , Wijnberg GJ, Kolwijck E, de Hullu JA, et al
    A patient with bilateral immature ovarian teratoma presenting with paraneoplastic encephalitis.
    Gynecol Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
83. SPENCER JA , Forstner R, Hricak H
    Investigating women with suspected ovarian cancer.
    Gynecol Oncol. 2007;.
    PubMed     Related articles   
    
    
    
84. GERARDI MA , Santillan A, Meisner B, Zahurak ML, et al
    A clinical pathway for patients undergoing primary cytoreductive surgery with rectosigmoid colectomy for advanced ovarian and primary peritoneal cancers.
    Gynecol Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
85. ROCCONI RP , Matthews KS, Kemper MK, Hoskins KE, et al
    Chemotherapy-related myelosuppression as a marker of survival in epithelial ovarian cancer patients.
    Gynecol Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
86. LIAVAAG AH , Dorum A, Bjoro T, Oksefjell H, et al
    A controlled study of sexual activity and functioning in epithelial ovarian cancer survivors. A therapeutic approach.
    Gynecol Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
87. ZIVANOVIC O , Eisenhauer EL, Zhou Q, Iasonos A, et al
    The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer.
    Gynecol Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
88. BROZEK I , Ochman K, Debniak J, Morzuch L, et al
    High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland.
    Gynecol Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
89. MOORE KN , Moxley KM, Fader AN, Axtell AE, et al
    Serous fallopian tube carcinoma: A retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary.
    Gynecol Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
90. LANDRUM LM , Gold MA, Moore KN, Myers TK, et al
    Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: A review of complications and completion rates.
    Gynecol Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
91. BAST RC , Thigpen JT, Arbuck SG, Basen-Engquist K, et al
    Clinical trial endpoints in ovarian cancer: Report of an FDA/ASCO/AACR Public Workshop.
    Gynecol Oncol. 2007;107:173-6.
    PubMed     Related articles    Abstract available
    
    
    
92. LANCASTER JM , Bethan Powell C, Kauff ND, Cass I, et al
    Society of gynecologic oncologists education committee statement on risk assessment for inherited gynecologic cancer predispositions.
    Gynecol Oncol. 2007;107:159-62.
    PubMed     Related articles    Abstract available
    
    
    October 2007
93. MORRIS CR , Rodriguez AO, Epstein J, Cress RD, et al
    Declining trends of epithelial ovarian cancer in California.
    Gynecol Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
94. CHU S , Alexiadis M, Fuller PJ
    Expression, mutational analysis and in vitro response of imatinib mesylate and nilotinib target genes in ovarian granulosa cell tumors.
    Gynecol Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
95. PATSNER B
    Re: Dr. Markman's editorial "Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials" Gynecol. Oncol. 106(2); 279-81: 2007.
    Gynecol Oncol. 2007;.
    PubMed     Related articles   
    
    
    
96. ERALP Y , Saip P, Aydin Z, Berkman S, et al
    Leptomeningeal dissemination of ovarian carcinoma through a ventriculoperitoneal shunt.
    Gynecol Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
97. SOUSSAN M , Wartski M, Cherel P, Fourme E, et al
    Impact of FDG PET-CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence.
    Gynecol Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
98. PENG B , Chang Q, Wang L, Hu Q, et al
    Suppression of human ovarian SKOV-3 cancer cell growth by Duchesnea phenolic fraction is associated with cell cycle arrest and apoptosis.
    Gynecol Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
99. CHI DS , Palayekar MJ, Sonoda Y, Abu-Rustum NR, et al
    Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma.
    Gynecol Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
100. RAKI M , Sarkioja M, Desmond RA, Chen DT, et al
     Oncolytic adenovirus Ad5/3-Delta24 and chemotherapy for treatment of orthotopic ovarian cancer.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
101. MARKMAN M
     Commentary entitled "Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials"
     Gynecol Oncol. 2007;.
     PubMed     Related articles   
     
     
     
102. CARTER J , Durfee J
     A case of bowel perforation after neoadjuvant chemotherapy for advanced epithelial ovarian cancer.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
103. CHAN JK , Kapp DS, Shin JY, Osann K, et al
     Factors associated with the suboptimal treatment of women less than 55 years of age with early-stage ovarian cancer.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
104. ALBERTS DS , Liu PY, Wilczynski SP, Clouser MC, et al
     Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest On
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
105. JOHNATTY SE , Nagle CM, Spurdle AB, Chen X, et al
     The MnSOD Val9Ala polymorphism, dietary antioxidant intake, risk and survival in ovarian cancer (Australia).
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
106. STADLMANN S , Dirnhofer S, Guth U, Thies S, et al
     ERCC1-immunoexpression does not predict platinum-resistance in ovarian cancer.
     Gynecol Oncol. 2007;.
     PubMed     Related articles   
     
     
     
107. CICIN I , Saip P, Eralp Y, Selam M, et al
     Ovarian carcinosarcomas: Clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
108. ZHANG Z , Yu Y, Xu F, Berchuck A, et al
     Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
109. CAREY MS , Bacon M, Tu D, Butler L, et al
     The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
110. RODEWALD M , Herr D, Schmitt W, Konrad R, et al
     Retroperitoneal vascular leakage in ovarian cancer is associated with increased VEGF.
     Gynecol Oncol. 2007;.
     PubMed     Related articles   
     
     
     
111. PECTASIDES D , Xiros N, Papaxoinis G, Aravantinos G, et al
     Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     September 2007
112. RAMIREZ PT , Landen CN Jr, Coleman RL, Milam MR, et al
     Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
113. ABUSHAHIN F , Singh DK, Lurain JR, Grendys EC, et al
     Weekly topotecan for recurrent platinum resistant ovarian cancer.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
114. KOLWIJCK E , Boss EA, van Altena AM, Beex LV, et al
     Stage IV epithelial ovarian carcinoma in an 18 year old patient presenting with a Sister Mary Joseph's nodule and metastasis in both breasts: A case report and review of the literature.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
115. RUNZ S , Keller S, Rupp C, Stoeck A, et al
     Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
116. SALDIVAR JS , Wu X, Follen M, Gershenson D, et al
     Nucleotide excision repair pathway review I: Implications in ovarian cancer and platinum sensitivity.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
117. HAVRILESKY LJ , Secord AA, Kulasingam S, Myers E, et al
     Management of platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
118. DOWDY SC , Mariani A, Bakkum JN, Cliby WA, et al
     Treatment of pulmonary recurrences in patients with endometrial cancer.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
119. ZOU C , Brewer M, Cao X, Zang R, et al
     Antitumor activity of 4-(N-hydroxyphenyl)retinamide conjugated with poly(l-glutamic acid) against ovarian cancer xenografts.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
120. SALANI R , Zahurak ML, Santillan A, Giuntoli RL 2nd, et al
     Survival impact of multiple bowel resections in patients undergoing primary cytoreductive surgery for advanced ovarian cancer: A case-control study.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
121. KUECK A , Opipari AW Jr, Griffith KA, Tan L, et al
     Resveratrol inhibits glucose metabolism in human ovarian cancer cells.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
122. BRINTON LA , Sakoda LC, Frederiksen K, Sherman ME, et al
     Relationships of uterine and ovarian tumors to pre-existing chronic conditions.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
123. SALDIVAR JS , Lu KH, Liang D, Gu J, et al
     Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
124. LI AJ , Elmore RG, Pavelka JC, Karlan BY, et al
     Hyperandrogenism, mediated by obesity and receptor polymorphisms, promotes aggressive epithelial ovarian cancer biology.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
125. GEISLER JP , Linnemeier GC, Thomas AJ, Manahan KJ, et al
     Extreme drug resistance is common after prior exposure to paclitaxel.
     Gynecol Oncol. 2007;106:538-40.
     PubMed     Related articles    Abstract available
     
     
     August 2007
126. DIAZ-MONTES TP , Zahurak ML, Bristow RE
     Predictors of extended intensive care unit resource utilization following surgery for ovarian cancer.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
127. WIMBERGER P , Heubner M, Otterbach F, Fehm T, et al
     Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
128. NAGAI Y , Inamine M, Hirakawa M, Kamiyama K, et al
     Postoperative whole abdominal radiotherapy in clear cell adenocarcinoma of the ovary.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
129. HOROWITZ NS , Hua J, Powell MA, Gibb RK, et al
     Novel cytotoxic agents from an unexpected source: Bile acids and ovarian tumor apoptosis.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
130. SMICUN Y , Gil O, Devine K, Fishman DA, et al
     S1P and LPA have an attachment-dependent regulatory effect on invasion of epithelial ovarian cancer cells.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
131. RASPOLLINI MR
     CA-125 level preoperative assessment in early and advanced ovarian carcinoma.
     Gynecol Oncol. 2007;.
     PubMed     Related articles   
     
     
     
132. VAN ALTENA AM , de Hullu JA, Massuger LF
     Letter commenting on the article "CA 125 expression pattern, prognosis and correlation with serum CA 125 in ovarian tumor patients" (104:508-515) by Hogdall, et al and on the Editorial "CA 125: Megadaltons of novel opportunities" (104:505-507).
     Gynecol Oncol. 2007;.
     PubMed     Related articles   
     
     
     
133. CHURA JC , Van Iseghem K, Downs LS Jr, Carson LF, et al
     Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
134. KOENSGEN D , Mustea A, Klaman I, Sun P, et al
     Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: Association with tumor progression.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
135. OBERMAIR A
     Preoperative serum CA125 in surgical stage 1 epithelial ovarian cancer.
     Gynecol Oncol. 2007;.
     PubMed     Related articles   
     
     
     
136. PIEK JM , Kenemans P, Zweemer RP, van Diest PJ, et al
     Ovarian carcinogenesis, an alternative theory.
     Gynecol Oncol. 2007;.
     PubMed     Related articles   
     
     
     
137. MARKMAN M
     The dilemma of carboplatin-associated hypersensitivity reactions in ovarian cancer management.
     Gynecol Oncol. 2007;.
     PubMed     Related articles   
     
     
     
138. HESS LM , Barakat R, Tian C, Ozols RF, et al
     Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: A Gynecologic Oncology Group study.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
139. BRISTOW RE , Santillan A, Salani R, Diaz-Montes TP, et al
     Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: A cost-effectiveness analysis.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
140. MARKMAN M
     Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials.
     Gynecol Oncol. 2007;106:279-81.
     PubMed     Related articles   
     
     
     
141. CHAN JK , Wu H, Cheung MK, Shin JY, et al
     The outcomes of 27,063 women with unstaged endometrioid uterine cancer.
     Gynecol Oncol. 2007;106:282-288.
     PubMed     Related articles    Abstract available
     
     
     
142. WITEK A , Paul-Samojedny M, Stojko R, Seifert B, et al
     Coexpression index of estrogen receptor alpha mRNA isoforms in simple, complex hyperplasia without atypia, complex atypical hyperplasia and adenocarcinoma.
     Gynecol Oncol. 2007;106:407-12.
     PubMed     Related articles    Abstract available
     
     
     
143. RAMIREZ PT , Milam MR, Frumovitz M
     Laparoscopic extraperitoneal para-aortic lymphadenectomy.
     Gynecol Oncol. 2007;106:433-4.
     PubMed     Related articles   
     
     
     July 2007
144. JORDAN SJ , Green AC, Whiteman DC, Webb PM, et al
     Risk factors for benign, borderline and invasive mucinous ovarian tumors: Epidemiological evidence of a neoplastic continuum?
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
145. SMITH CJ , Heeren M, Nicklin JL, Perrin LC, et al
     Efficacy of routine follow-up in patients with recurrent uterine cancer.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
146. SIMPKINS F , Belinson JL, Rose PG
     Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
147. TEMPFER CB , Polterauer S, Bentz EK, Reinthaller A, et al
     Accuracy of intraoperative frozen section analysis in borderline tumors of the ovary: A retrospective analysis of 96 cases and review of the literature.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
148. WALKER G , Macleod K, Williams AR, Cameron DA, et al
     Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
149. SCHOLZ HS , Tasdemir H, Hunlich T, Turnwald W, et al
     Multivisceral cytoreductive surgery in FIGO stages IIIC and IV epithelial ovarian cancer: Results and 5-year follow-up.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
150. HARRISON ML , Gore ME, Spriggs D, Kaye S, et al
     Duration of second or greater complete clinical remission in ovarian cancer: Exploring potential endpoints for clinical trials.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
151. FERRANDINA G , Legge F, Petrillo M, Salutari V, et al
     Ovarian cancer patients with "node-positive-only" Stage IIIC disease have a more favorable outcome than Stage IIIA/B.
     Gynecol Oncol. 2007;.
     PubMed     Related articles   
     
     
     
152. BLACK D , Iasonos A, Ahmed H, Chi DS, et al
     Effect of perioperative venous thromboembolism on survival in ovarian, primary peritoneal, and fallopian tube cancer.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
153. GERSHENSON DM , Birrer M
     Time for action: A "sea change" in treatment strategies for rare types of epithelial ovarian cancer.
     Gynecol Oncol. 2007;106:1-3.
     PubMed     Related articles   
     
     
     
154. GEOMINI PM , Coppus SF, Kluivers KB, Bremer GL, et al
     Is three-dimensional ultrasonography of additional value in the assessment of adnexal masses?
     Gynecol Oncol. 2007;106:153-9.
     PubMed     Related articles    Abstract available
     
     
     
155. LIN LL , Mutch DG, Rader JS, Powell MA, et al
     External radiotherapy versus vaginal brachytherapy for patients with intermediate risk endometrial cancer.
     Gynecol Oncol. 2007;106:215-20.
     PubMed     Related articles    Abstract available
     
     
     
156. EITAN R , Galoyan N, Zuckerman B, Shaya M, et al
     The risk of malignancy in post-menopausal women presenting with adnexal torsion.
     Gynecol Oncol. 2007;106:211-4.
     PubMed     Related articles    Abstract available
     
     
     
157. SEIDMAN JD , Wang BG
     Evaluation of normal-sized ovaries associated with primary peritoneal serous carcinoma for possible precursors of ovarian serous carcinoma.
     Gynecol Oncol. 2007;106:201-6.
     PubMed     Related articles    Abstract available
     
     
     
158. STROSBERG J , Nasir A, Cragun J, Gardner N, et al
     Metastatic carcinoid tumor to the ovary: a clinicopathologic analysis of seventeen cases.
     Gynecol Oncol. 2007;106:65-8.
     PubMed     Related articles    Abstract available
     
     
     
159. HOGG R , Scurry J, Kim SN, Friedlander M, et al
     Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma.
     Gynecol Oncol. 2007;106:44-51.
     PubMed     Related articles    Abstract available
     
     
     June 2007
160. ETTER AL , Bassi I, Germain S, Delaloye JF, et al
     The combination of chemotherapy and intraperitoneal MegaFas Ligand improves treatment of ovarian carcinoma.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
161. ALETTI GD , Santillan A, Eisenhauer EL, Hu J, et al
     A new frontier for quality of care in gynecologic oncology surgery: Multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
162. TEBES SJ , Sayer RA, Palmer JM, Tebes CC, et al
     Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
163. OHISHI Y , Kaku T, Oya M, Kobayashi H, et al
     CD56 expression in ovarian granulosa cell tumors, and its diagnostic utility and pitfalls.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
164. BERMUDEZ Y , Yang H, Saunders BO, Cheng JQ, et al
     VEGF- and LPA-induced telomerase in human ovarian cancer cells is Sp1-dependent.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
165. LI J , Yang W, Wu X
     Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: a study in Chinese patients.
     Gynecol Oncol. 2007;105:769-75.
     PubMed     Related articles    Abstract available
     
     
     
166. BRUN JL
     Demons syndrome revisited: a review of the literature.
     Gynecol Oncol. 2007;105:796-800.
     PubMed     Related articles    Abstract available
     
     
     
167. MARKMAN M
     A relevant historical perspective on the current toxicity of IP chemotherapy: implications for the future.
     Gynecol Oncol. 2007;105:561-2.
     PubMed     Related articles   
     
     
     
168. MCCORMICK CC , Giuntoli RL 2nd, Gardner GJ, Schulick RD, et al
     The role of cytoreductive surgery for colon cancer metastatic to the ovary.
     Gynecol Oncol. 2007;105:791-5.
     PubMed     Related articles    Abstract available
     
     
     
169. DAINTY LA , Risinger JI, Morrison C, Chandramouli GV, et al
     Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma.
     Gynecol Oncol. 2007;105:563-70.
     PubMed     Related articles    Abstract available
     
     
     
170. LEISER AL , Chi DS, Ishill NM, Tew WP, et al
     Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience.
     Gynecol Oncol. 2007;105:657-61.
     PubMed     Related articles    Abstract available
     
     
     
171. CHOI CH , Kim TJ, Kim WY, Ahn GH, et al
     Papillary serous carcinoma in ovaries of normal size: a clinicopathologic study of 20 cases and comparison with extraovarian peritoneal papillary serous carcinoma.
     Gynecol Oncol. 2007;105:762-8.
     PubMed     Related articles    Abstract available
     
     
     
172. ARMSTRONG DK , Bookman MA, McGuire W, Bristow RE, et al
     A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study.
     Gynecol Oncol. 2007;105:667-71.
     PubMed     Related articles    Abstract available
     
     
     
173. CHAMPION V , Williams SD, Miller A, Reuille KM, et al
     Quality of life in long-term survivors of ovarian germ cell tumors: a Gynecologic Oncology Group study.
     Gynecol Oncol. 2007;105:687-94.
     PubMed     Related articles    Abstract available
     
     
     
174. OHISHI Y , Oda Y, Basaki Y, Kobayashi H, et al
     Expression of beta-tubulin isotypes in human primary ovarian carcinoma.
     Gynecol Oncol. 2007;105:586-92.
     PubMed     Related articles    Abstract available
     
     
     
175. TASSI RA , Bignotti E, Rossi E, Falchetti M, et al
     Overexpression of mammaglobin B in epithelial ovarian carcinomas.
     Gynecol Oncol. 2007;105:578-85.
     PubMed     Related articles    Abstract available
     
     
     
176. SHVARTSMAN HS , Sun CC, Bodurka DC, Mahajan V, et al
     Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma.
     Gynecol Oncol. 2007;105:625-9.
     PubMed     Related articles    Abstract available
     
     
     May 2007
177. HOGDALL EV , Christensen L, Kjaer SK, Blaakaer J, et al
     Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer From the Danish "MALOVA" Ovarian Cancer Study.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
178. WELCH S , Hirte HW, Carey MS, Hotte SJ, et al
     UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: A study of the Princess Margaret Hospital Phase II consortium.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
179. MARKMAN M
     Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer.
     Gynecol Oncol. 2007;.
     PubMed     Related articles   
     
     
     
180. BADGWELL D , Lu Z, Cole L, Fritsche H, et al
     Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
181. LEE S , Garner EI, Welch WR, Berkowitz RS, et al
     Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
182. EISENHAUER EL , Tew WP, Levine DA, Lichtman SM, et al
     Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
183. MIYATAKE T , Tringler B, Liu W, Liu SH, et al
     B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
184. CADRON I , Leunen K, Amant F, Van Gorp T, et al
     The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
185. NISHIO S , Sugiyama T, Shouji T, Yoshizaki A, et al
     Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancer.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
186. SIMON I , Katsaros D, Rigault de la Longrais I, Massobrio M, et al
     B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
187. ELIT L , Zitzelsberger L, Fung-Kee-Fung M, Brouwers M, et al
     Use of systemic therapy in women with recurrent ovarian cancer-Development of a national clinical practice guideline.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
188. LENTZ SS , Miller BE, Kucera GL, Levine EA, et al
     Intraperitoneal hyperthermic chemotherapy using carboplatin: A phase I analysis in ovarian carcinoma.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
189. STEVINSON C , Faught W, Steed H, Tonkin K, et al
     Associations between physical activity and quality of life in ovarian cancer survivors.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
190. LE T , Williams K, Senterman M, Hopkins L, et al
     Histopathologic assessment of chemotherapy effects in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
191. SIMON I , Liu Y, Krall KL, Urban N, et al
     Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
192. SECORD AA , Darcy KM, Hutson A, Lee PS, et al
     Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: A Gynecologic Oncology Group study.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
193. RECCHIA F , Saggio G, Amiconi G, Di Blasio A, et al
     A multicenter phase II study of pegylated liposomal doxorubicin and oxaliplatin in recurrent ovarian cancer.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
194. HUANG JY , Buckett WM, Gilbert L, Tan SL, et al
     Retrieval of immature oocytes followed by in vitro maturation and vitrification: a case report on a new strategy of fertility preservation in women with borderline ovarian malignancy.
     Gynecol Oncol. 2007;105:542-4.
     PubMed     Related articles    Abstract available
     
     
     
195. MARCHAND V , Graveleau J, Lanctin-Garcia C, Bourbouloux E, et al
     A rare gynecological case of paraneoplastic cerebellar degeneration discovered by FDG-PET.
     Gynecol Oncol. 2007;105:545-7.
     PubMed     Related articles    Abstract available
     
     
     
196. OHISHI Y , Kaku T, Kaneki E, Wake N, et al
     Malignant ovarian tumor composed of endometrioid adenocarcinoma, clear cell adenocarcinoma, squamous cell carcinoma, yolk sac tumor and immature teratoma with prominent neuroectodermal and rhabdomyosarcomatous differentiation: a case study.
     Gynecol Oncol. 2007;105:548-52.
     PubMed     Related articles    Abstract available
     
     
     
197. LEWIS MR , Euscher ED, Deavers MT, Silva EG, et al
     Metastatic colorectal adenocarcinoma involving the ovary with elevated serum CA125: a potential diagnostic pitfall.
     Gynecol Oncol. 2007;105:395-8.
     PubMed     Related articles    Abstract available
     
     
     
198. MOM CH , Engelen MJ, Willemse PH, Gietema JA, et al
     Granulosa cell tumors of the ovary: the clinical value of serum inhibin A and B levels in a large single center cohort.
     Gynecol Oncol. 2007;105:365-72.
     PubMed     Related articles    Abstract available
     
     
     
199. SUGA S , Kato K, Ohgami T, Yamayoshi A, et al
     An inhibitory effect on cell proliferation by blockage of the MAPK/estrogen receptor/MDM2 signal pathway in gynecologic cancer.
     Gynecol Oncol. 2007;105:341-50.
     PubMed     Related articles    Abstract available
     
     
     
200. OMURA GA
     Re: early stage high-risk ovarian cancer.
     Gynecol Oncol. 2007;105:555-6.
     PubMed     Related articles   
     
     
     
201. ESTES JM , Oliver PG, Straughn JM Jr, Zhou T, et al
     Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model.
     Gynecol Oncol. 2007;105:291-8.
     PubMed     Related articles    Abstract available
     
     
     
202. YILMAZ I , Baloglu H, Haholu A, Berber U, et al
     Objective risk definition for endometrial lesion spectrum: a diagnostic algorithm.
     Gynecol Oncol. 2007;105:451-6.
     PubMed     Related articles    Abstract available
     
     
     
203. CROTZER DR , Sun CC, Coleman RL, Wolf JK, et al
     Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.
     Gynecol Oncol. 2007;105:404-8.
     PubMed     Related articles    Abstract available
     
     
     
204. CROTZER DR , Wolf JK, Gano JB, Gershenson DM, et al
     A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary.
     Gynecol Oncol. 2007;105:399-403.
     PubMed     Related articles    Abstract available
     
     
     
205. VILLEDIEU M , Briand M, Duval M, Heron JF, et al
     Anticancer and chemosensitizing effects of 2,3-DCPE in ovarian carcinoma cell lines: link with ERK activation and modulation of p21WAF1/CIP1, Bcl-2 and Bcl-xL expression.
     Gynecol Oncol. 2007;105:373-84.
     PubMed     Related articles    Abstract available
     
     
     April 2007
206. BRISTOW RE , Chi DS
     Platinum-based neoadjuvant chemotherapy for advanced ovarian cancer: A meta-analysis.
     Gynecol Oncol. 2007;.
     PubMed     Related articles   
     
     
     
207. MARKMAN M
     Platinum-based neoadjuvant chemotherapy for advanced ovarian cancer.
     Gynecol Oncol. 2007;.
     PubMed     Related articles   
     
     
     
208. GEISLER JP , Linnemeier GC, Thomas AJ, Manahan KJ, et al
     Nutritional assessment using prealbumin as an objective criterion to determine whom should not undergo primary radical cytoreductive surgery for ovarian cancer.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
209. BAE JH , Lee JM, Ryu KS, Lee YS, et al
     Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery.
     Gynecol Oncol. 2007;.
     PubMed     Related articles    Abstract available
     
     
     
210. VERNOOIJ F , Peter A, Heintz M, Witteveen E, et al
     The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: A systematic review.